Descrizione del progetto
Un nuovo farmaco per il trattamento dell’aplasia midollare
La chemioterapia convenzionale è aspecifica e colpisce sia le cellule normali che quelle tumorali. Ciò causa anemia, che in alcuni casi può essere grave e portare all’aplasia, l’incapacità del midollo osseo di produrre una quantità sufficiente di globuli bianchi o rossi. L’aplasia colpisce anche il sistema immunitario, rendendo i pazienti più suscettibili alle infezioni. Per affrontare questo problema medico, il progetto ExitAplasia, finanziato dall’UE, ha sviluppato un nuovo farmaco che favorisce la rapida rigenerazione del sistema sanguigno dopo la chemioterapia. Questo nuovo farmaco riduce il tempo di ospedalizzazione e, pertanto, la possibilità di contrarre infezioni, migliorando il risultato clinico dei pazienti trattati con la chemioterapia.
Obiettivo
With more than 3.7 million new cases and 1.9 million deaths each year, cancer represents the second most important cause of death and morbidity in Europe; a significant portion is treated by chemotherapy, which triggers the destruction of red and white blood cells: aplasia. This aggressive treatment results in a severe deficient immunity and an extremely fragile health, which causes patients with leukaemia, for example, to stay 21 days at the hospital in a sterile room costing in average €25,000 per day. In this extremely difficult situation, RegStem has found the high-potential solution: the new Reg-X310 medicine which allows faster red and white blood cells regeneration, accelerating exit from aplasia and shortening hospital length of stay of at least 4 days. It is a tremendous improvement in relation to only existing medicine that speeds out aplasia for only one day. This breakthrough innovation will speed up recovery, decrease the risk of dying from a hospital-acquired infection (~7% less), and decrease healthcare cost for around €100,000/patient. Reg-X310 is a game-changing innovation which will substantially improve the treatment of aplasia and disrupt the market. Reg-X310 is being developed by RegStem, a French awarded innovative company, founded as a spin-off of the world-famous Pasteur Institute in Paris. The ExitAplasia project will allow the company to reformulate the Reg-X310 into an intravenous injection and to start the toxicological and clinical validation as well as the CE marking, necessary for the commercialisation in Europe. To accomplish this goal, RegStem will complete a feasibility study to further analyse users’ pain points and actual trends, as well as broaden European key stakeholder networks and explore new business opportunity. RegStem will lead the European and global acute leukaemia market with 10% market share in 2023 and up to 70% before 2027, which will result in €14 and €99 million turnover, and more than 20 new European jobs
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
75014 PARIS
Francia
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.